These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 19039321)

  • 1. Pathogenesis of myeloma bone disease.
    Roodman GD
    Leukemia; 2009 Mar; 23(3):435-41. PubMed ID: 19039321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenesis of myeloma bone disease.
    Roodman GD
    J Cell Biochem; 2010 Feb; 109(2):283-91. PubMed ID: 20014067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
    Kupisiewicz K
    Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel targets for myeloma bone disease.
    Roodman GD
    Expert Opin Ther Targets; 2008 Nov; 12(11):1377-87. PubMed ID: 18851694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the pathogenesis of osteolysis in multiple myeloma patients.
    Giuliani N; Colla S; Rizzoli V
    Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathophysiology of multiple myeloma bone disease.
    Lentzsch S; Ehrlich LA; Roodman GD
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1035-49, viii. PubMed ID: 17996587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenesis of myeloma bone disease.
    Roodman GD
    Blood Cells Mol Dis; 2004; 32(2):290-2. PubMed ID: 15003820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of bortezomib on bone disease in multiple myeloma.
    Drake MT; Rajkumar SV
    Am J Hematol; 2009 Jan; 84(1):1-2. PubMed ID: 19030185
    [No Abstract]   [Full Text] [Related]  

  • 9. Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
    Oyajobi BO; Mundy GR
    Cancer; 2003 Feb; 97(3 Suppl):813-7. PubMed ID: 12548580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The multiple myeloma bone eco-system and its relation to oncogenesis.
    Bataille R
    Morphologie; 2015 Jun; 99(325):31-7. PubMed ID: 26005000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The critical role of interleukin-6, interleukin-1B and macrophage colony-stimulating factor in the pathogenesis of bone lesions in multiple myeloma.
    Bataille R; Chappard D; Klein B
    Int J Clin Lab Res; 1992; 21(4):283-7. PubMed ID: 1591381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hypercalcemia in myeloma].
    Abe M
    Nihon Rinsho; 2007 Dec; 65(12):2245-9. PubMed ID: 18069268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloma bone disease and treatment options.
    Yeh HS; Berenson JR
    Eur J Cancer; 2006 Jul; 42(11):1554-63. PubMed ID: 16797971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Myeloma bone disease and RANKL signaling].
    Abe M
    Clin Calcium; 2011 Aug; 21(8):1167-74. PubMed ID: 21814021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloma and Bone Disease.
    Panaroni C; Yee AJ; Raje NS
    Curr Osteoporos Rep; 2017 Oct; 15(5):483-498. PubMed ID: 28861842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bone disease in multiple myeloma and its mechanism].
    Abe M
    Clin Calcium; 2006 Apr; 16(4):565- 71. PubMed ID: 16582506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Multiple myeloma].
    Abe M
    Nihon Rinsho; 2009 May; 67(5):991-5. PubMed ID: 19432122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma.
    Terpos E; Dimopoulos MA; Sezer O
    Leukemia; 2007 Sep; 21(9):1875-84. PubMed ID: 17611556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
    Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
    J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.
    Oyajobi BO; Franchin G; Williams PJ; Pulkrabek D; Gupta A; Munoz S; Grubbs B; Zhao M; Chen D; Sherry B; Mundy GR
    Blood; 2003 Jul; 102(1):311-9. PubMed ID: 12649140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.